PLRX

Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.

Wall Street analysts forecast PLRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLRX is 3.00 USD with a low forecast of 2.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Pliant Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Pliant Therapeutics Inc. EPS for the last quarter amounts to -0.43 USD, decreased -54.74 % YoY.

Pliant Therapeutics Inc (PLRX) has 171 emplpoyees as of December 15 2025.

Today PLRX has the market capitalization of 75.58M USD.